MIRUM meets primary endpoint in hepatitis delta drug trial

April 27, 2026 8:00 AM

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) announced that its experimental drug brelovitug met the primary endpoint in a Phase 2b study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found